Abbott: Crohn Disease trials

The registry lists 17 Crohn Disease studies with Abbott as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 2 7Phase 3 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Remission in Subjects With Crohn's Disease, Open Label ExtensionCompletedNCT01070303Phase 3Results posted
• A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's DiseaseCompletedNCT00445939Phase 2/3Results posted
• A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's DiseaseCompletedNCT00445432Phase 2/3Results posted
• Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)CompletedNCT00427921Phase 3Results posted
• Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's DiseaseCompletedNCT00409682Phase 3Results posted
• Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's DiseaseCompletedNCT00409617Phase 3Results posted
• Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the ColonCompletedNCT00348283Phase 3Results posted
• Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's DiseaseCompletedNCT00195715Phase 3Results posted
• Remission in Subjects With Crohn's Disease, 1 Year PhaseCompletedNCT00055497Phase 3Results posted
• Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's DiseaseTerminatedNCT00562887Phase 2
• Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)CompletedNCT00338650Phase 3
• Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's DiseaseCompletedNCT00267722Phase 2
• Visilizumab for Treatment of Perianal Fistulas in Crohn's DiseaseCompletedNCT00267709Phase 2
• Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's DiseaseCompletedNCT00105300Phase 3
• Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's DiseaseCompletedNCT00077779Phase 3
• A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's DiseaseCompletedNCT00072943Phase 2
• A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's DiseaseCompletedNCT00055523Phase 2